1-2 of 2
Fabrizio Ciambelli, MD
Close
Sort by
Journal Articles

Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials

Alessandra Larocca, Massimo Offidani, MD, Pellegrino Musto, MD, Francesca Patriarca, MD, Lorenzo De Paoli, MD, Paolo Corradini, MD, Marco Salvini, MD, Clotilde Cangialosi, MD, Tommasina Guglielmelli, MD, Giovannino Ciccone, Fausto Dore, MD, Angelo Belotti, MD, Mattia D'Agostino, MD, Felicetto Ferrara, MD, Daniela Oddolo, Riccardo Centurioni, MD, Fabrizio Ciambelli, MD, Stefano Spada, Donatella Iolanda Vincelli, MD, Michele Cavo, MD, Nicola Giuliani, MD PhD, Alberto Bosi, MD, Concetta Conticello, MD, Roberto Ria, MD, Maria Teresa Petrucci, MD, Mario Boccadoro
Journal: Blood
Blood (2017) 130 (Supplement 1): 744.
https://doi.org/10.1182/blood.V130.Suppl_1.744.744
Published: 2017
Journal Articles

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Paola Tacchetti, MD, Lucia Pantani, MD, Valerio De Stefano, MD, Elena Zamagni, MD, Jacopo Peccatori, MD, Annalisa Pezzi, Statistician, Catello Califano, MD, Andrea Nozza, MD, Patrizia Tosi, MD, Carolina Terragna, PhD, Fabrizio Ciambelli, MD, Delia Cangini, MD, Piero Galieni, MD, Clotilde Cangialosi, MD, Giovanni De Sabbata, MD, Francesca Elice, MD, Antonio Palumbo, MD, Michele Cavo, MD
Journal: Blood
Blood (2014) 124 (21): 196.
https://doi.org/10.1182/blood.V124.21.196.196
Published: 2014